docetaxel anhydrous has been researched along with Ductal, Lobular, and Medullary Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, KR; Gil, EY; Jeong, H; Jo, UH; Kim, A; Kim, YH; Koh, I; Lee, ES; Park, KH; Seo, JH; Whang, YM; Woo, OH | 1 |
| Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U | 1 |
2 other study(ies) available for docetaxel anhydrous and Ductal, Lobular, and Medullary Neoplasms
| Article | Year |
|---|---|
Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer.
Topics: Adult; Antineoplastic Agents; Apoptosis; Base Sequence; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Docetaxel; Down-Regulation; Epigenesis, Genetic; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Logistic Models; Multivariate Analysis; Neoplasms, Ductal, Lobular, and Medullary; Promoter Regions, Genetic; Sequence Analysis, DNA; Taxoids; Tubulin Modulators; Tumor Suppressor Proteins | 2012 |
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid | 2004 |